Skip to main content

Advertisement

SpringerLink
Log in

Treatment Options in the Management of Status Epilepticus

  • Critical Care Neurology
  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

Status epilepticus treatment involves the use of several pharmacologic compounds, which are conceptually divided into three successive and additional lines of action. Because of their rapid onset of action, benzodiazepines represent the first approach; these are followed by classic antiepileptic drugs that are administered intravenously. In refractory episodes, pharmacologic coma induction with an appropriate anesthetic is advocated. Apart from first-line compounds, the level of evidence for medications used in status epilepticus is extremely limited. It is important to specifically address etiology in order to maximize the impact of the antiepileptic therapy. Fine-tuning of the treatment strategy, mainly regarding the choice of whether to induce coma, should be approached by balancing the benefits of rapid control of the status epilepticus with the risks of adverse effects. Although each status epilepticus episode should be treated as rapidly as possible, it appears advisable to reserve coma induction for those forms, such as generalized convulsive status, that have been shown to present a consistent risk of neurologic sequelae.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance, •• Of major importance

  1. Chen JW, Wasterlain CG: Status epilepticus: pathophysiology and management in adults. Lancet Neurol 2006, 5(3):246–256.

    Article  PubMed  Google Scholar 

  2. Lowenstein DH, Alldredge BK: Status epilepticus. N Engl J Med 1998, 338(14):970–976.

    Article  CAS  PubMed  Google Scholar 

  3. Lowenstein DH, Bleck T, Macdonald RL: It’s time to revise the definition of status epilepticus. Epilepsia 1999, 40(1):120–122.

    Article  CAS  PubMed  Google Scholar 

  4. Mazarati AM, Wasterlain CG: N-methyl-D-aspartate receptor antagonists abolish the maintenance phase of self-sustaining status epilepticus in rat. Neurosci Lett 1999, 265(3):187–190.

    Article  CAS  PubMed  Google Scholar 

  5. Holtkamp M, Othman J, Buchheim K, Meierkord H: Diagnosis of psychogenic nonepileptic status epilepticus in the emergency setting. Neurology 2006, 66(11):1727–1729.

    Article  PubMed  Google Scholar 

  6. Leppik IE, Derivan AT, Homan RW, et al.: Double-blind study of lorazepam and diazepam in status epilepticus. JAMA 1983, 249(11):1452–1454.

    Article  CAS  PubMed  Google Scholar 

  7. Alldredge BK, Gelb AM, Isaacs SM, et al.: A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med 2001, 345(9):631–637.

    Article  CAS  PubMed  Google Scholar 

  8. Treiman DM, Meyers PD, Walton NY, et al.: A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med 1998, 339(12):792–798.

    Article  CAS  PubMed  Google Scholar 

  9. Treiman DM, Walton NY, Collins JF, VA Status Epilepticus Cooperative Study Group: Treatment of status epilepticus if first drug fails [abstract J.02]. Epilepsia 1999, 40(Suppl 7):243.

    Google Scholar 

  10. Treiman DM: Pharmacokinetics and clinical use of benzodiazepines in the management of status epilepticus. Epilepsia 1989, 30(Suppl 2):S4–S10.

    Article  PubMed  Google Scholar 

  11. Browne TR: The pharmacokinetics of agents used to treat status epilepticus. Neurology 1990, 40(5 Suppl 2):28–32.

    CAS  PubMed  Google Scholar 

  12. Crevoisier C, Delisle MC, Joseph I, Foletti G: Comparative single-dose pharmacokinetics of clonazepam following intravenous, intramuscular and oral administration to healthy volunteers. Eur Neurol 2003, 49(3):173–177.

    Article  CAS  PubMed  Google Scholar 

  13. McIntyre J, Robertson S, Norris E, et al.: Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. Lancet 2005, 366(9481):205–210.

    Article  CAS  PubMed  Google Scholar 

  14. Misra UK, Kalita J, Patel R: Sodium valproate vs phenytoin in status epilepticus: a pilot study. Neurology 2006, 67(2):340–342.

    Article  CAS  PubMed  Google Scholar 

  15. Sheth RD, Gidal BE: Intravenous valproic acid for myoclonic status epilepticus. Neurology 2000, 54(5):1201.

    CAS  PubMed  Google Scholar 

  16. Agarwal P, Kumar N, Chandra R, et al.: Randomized study of intravenous valproate and phenytoin in status epilepticus. Seizure 2007, 16(6):527–532.

    Article  PubMed  Google Scholar 

  17. Gilad R, Izkovitz N, Dabby R, et al.: Treatment of status epilepticus and acute repetitive seizures with i.v. valproic acid vs phenytoin. Acta Neurol Scand 2008, 118(5):296–300.

    Article  CAS  PubMed  Google Scholar 

  18. Rossetti AO, Bromfield EB: Determinants of success in the use of oral levetiracetam in status epilepticus. Epilepsy Behav 2006, 8(3):651–654.

    Article  PubMed  Google Scholar 

  19. • Ruegg S, Naegelin Y, Hardmeier M, et al.: Intravenous levetiracetam: treatment experience with the first 50 critically ill patients. Epilepsy Behav 2008, 12(3):477–480.

    Article  PubMed  Google Scholar 

  20. • Knake S, Gruener J, Hattemer K, et al.: Intravenous levetiracetam in the treatment of benzodiazepine refractory status epilepticus. J Neurol Neurosurg Psychiatry 2008, 79(5):588–589.

    Article  CAS  PubMed  Google Scholar 

  21. • Kellinghaus C, Berning S, Besselmann M: Intravenous lacosamide as successful treatment for nonconvulsive status epilepticus after failure of first-line therapy. Epilepsy Behav 2009, 14(2):429–431.

    Article  PubMed  Google Scholar 

  22. Walton NY, Uthman BM, El Yafi K, et al.: Phenytoin penetration into brain after administration of phenytoin or fosphenytoin. Epilepsia 1999, 40(2):153–156.

    Article  CAS  PubMed  Google Scholar 

  23. Yu KT, Mills S, Thompson N, Cunanan C: Safety and efficacy of intravenous valproate in pediatric status epilepticus and acute repetitive seizures. Epilepsia 2003, 44(5):724–726.

    Article  CAS  PubMed  Google Scholar 

  24. Perucca E: Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002, 16(10):695–714.

    Article  CAS  PubMed  Google Scholar 

  25. Sinha S, Naritoku DK: Intravenous valproate is well tolerated in unstable patients with status epilepticus. Neurology 2000, 55(5):722–724.

    CAS  PubMed  Google Scholar 

  26. Edwards KR, Glantz MJ: The pharmacokinetics of levetiracetam in human cerebrospinal fluid and serum: a controlled dose-ranging study in malignant brain-tumor patients. Epilepsia 2004, 45(Suppl 7):121.

    Google Scholar 

  27. Fountain NB, Lothman EW: Pathophysiology of status epilepticus. J Clin Neurophysiol 1995, 12(4):326–342.

    CAS  PubMed  Google Scholar 

  28. •• Holtkamp M: The anaesthetic and intensive care of status epilepticus. Curr Opin Neurol 2007, 20(2):188–193.

    Article  CAS  PubMed  Google Scholar 

  29. Claassen J, Hirsch LJ, Emerson RG, Mayer SA: Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia 2002, 43(2):146–153.

    Article  CAS  PubMed  Google Scholar 

  30. Rossetti AO, Logroscino G, Bromfield EB: Refractory status epilepticus: effect of treatment aggressiveness on prognosis. Arch Neurol 2005, 62(11):1698–1702.

    Article  PubMed  Google Scholar 

  31. Bayliff CD, Schwartz ML, Hardy BG: Pharmacokinetics of high-dose pentobarbital in severe head trauma. Clin Pharmacol Ther 1985, 38(4):457–461.

    CAS  PubMed  Google Scholar 

  32. Wessen A, Persson PM, Nilsson A, Hartvig P: Clinical pharmacokinetics of propofol given as a constant-rate infusion and in combination with epidural blockade. J Clin Anesth 1994, 6(3):193–198.

    Article  CAS  PubMed  Google Scholar 

  33. Vasile B, Rasulo F, Candiani A, Latronico N: The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intensive Care Med 2003, 29(9):1417–1425.

    Article  PubMed  Google Scholar 

  34. • Zarovnaya EL, Jobst BC, Harris BT: Propofol-associated fatal myocardial failure and rhabdomyolysis in an adult with status epilepticus. Epilepsia 2007, 48(5):1002–1006.

    Article  PubMed  Google Scholar 

  35. Rossetti AO, Reichhart MD, Schaller MD, et al.: Propofol treatment of refractory status epilepticus: a study of 31 episodes. Epilepsia 2004, 45(7):757–763.

    Article  CAS  PubMed  Google Scholar 

  36. Naritoku DK, Sinha S: Prolongation of midazolam half-life after sustained infusion for status epilepticus. Neurology 2000, 54(6):1366–1368.

    CAS  PubMed  Google Scholar 

  37. Claassen J, Hirsch LJ, Emerson RG, et al.: Continuous EEG monitoring and midazolam infusion for refractory nonconvulsive status epilepticus. Neurology 2001, 57(6):1036–1042.

    CAS  PubMed  Google Scholar 

  38. • Rossetti AO, Logroscino G, Milligan TA, et al.: Status Epilepticus Severity Score (STESS): a tool to orient early treatment strategy. J Neurol 2008, 255(10):1561–1566.

    Article  PubMed  Google Scholar 

  39. • Drislane FW, Blum AS, Lopez MR, et al.: Duration of refractory status epilepticus and outcome: loss of prognostic utility after several hours. Epilepsia 2009, 50(6):1566–1571.

    Article  PubMed  Google Scholar 

  40. Holtkamp M, Othman J, Buchheim K, et al.: A “malignant” variant of status epilepticus. Arch Neurol 2005, 62(9):1428–1431.

    Article  PubMed  Google Scholar 

  41. • Pruss H, Holtkamp M: Ketamine successfully terminates malignant status epilepticus. Epilepsy Res 2008, 82(2–3):219–222.

    Article  PubMed  Google Scholar 

  42. Mirsattari SM, Sharpe MD, Young GB: Treatment of refractory status epilepticus with inhalational anesthetic agents isoflurane and desflurane. Arch Neurol 2004, 61(8):1254–1259.

    Article  PubMed  Google Scholar 

  43. Towne AR, Garnett LK, Waterhouse EJ, et al.: The use of topiramate in refractory status epilepticus. Neurology 2003, 60(2):332–334.

    CAS  PubMed  Google Scholar 

  44. Iannetti P, Spalice A, Parisi P: Calcium-channel blocker verapamil administration in prolonged and refractory status epilepticus. Epilepsia 2005, 46(6):967–969.

    Article  PubMed  Google Scholar 

  45. Bodenant M, Moreau C, Sejourne C, et al.: [Interest of the ketogenic diet in a refractory status epilepticus in adults]. Rev Neurol (Paris) 2008, 164(2):194–199.

    CAS  Google Scholar 

  46. Robakis TK, Hirsch LJ: Literature review, case report, and expert discussion of prolonged refractory status epilepticus. Neurocrit Care 2006, 4(1):35–46.

    Article  CAS  PubMed  Google Scholar 

  47. De Herdt V, Waterschoot L, Vonck K, et al.: Vagus nerve stimulation for refractory status epilepticus. Eur J Paediatr Neurol 2009, 13(3):286–289.

    Article  PubMed  Google Scholar 

  48. • Corry JJ, Dhar R, Murphy T, Diringer MN: Hypothermia for refractory status epilepticus. Neurocrit Care 2008, 9(2):189–197.

    Article  CAS  PubMed  Google Scholar 

  49. Lhatoo SD, Alexopoulos AV: The surgical treatment of status epilepticus. Epilepsia 2007, 48(Suppl 8):61–65.

    Article  PubMed  Google Scholar 

  50. Jordan KG, Hirsch LJ: In nonconvulsive status epilepticus (NCSE), treat to burst-suppression: pro and con. Epilepsia 2006, 47(Suppl 1):41–45.

    Article  PubMed  Google Scholar 

  51. Kaplan PW: No, some types of nonconvulsive status epilepticus cause little permanent neurologic sequelae (or: “the cure may be worse than the disease”). Neurophysiol Clin 2000, 30(6):377–382.

    Article  CAS  PubMed  Google Scholar 

  52. Cereda C, Berger MM, Rossetti AO: Bowel ischemia: a rare complication of thiopental treatment for status epilepticus. Neurocrit Care 2009, 10(3):355–358.

    Article  PubMed  Google Scholar 

  53. • Rossetti AO, Oddo M, Liaudet L, Kaplan PW: Predictors of awakening from postanoxic status epilepticus after therapeutic hypothermia. Neurology 2009, 72(8):744–749.

    Article  PubMed  Google Scholar 

  54. Dara SI, Tungpalan LA, Manno EM, et al.: Prolonged coma from refractory status epilepticus. Neurocrit Care 2006, 4(2):140–142.

    Article  PubMed  Google Scholar 

Download references

Disclosure

Dr. Rossetti has received speaker fees from UCB, has prepared scientific publications for Janssen-Cilag, and has received research support from Pfizer and UCB.

Author information

Authors and Affiliations

  1. Service de Neurologie, CHUV-BH07, CH-1011, Lausanne, Switzerland

    Andrea O. Rossetti

Authors
  1. Andrea O. Rossetti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrea O. Rossetti.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rossetti, A.O. Treatment Options in the Management of Status Epilepticus. Curr Treat Options Neurol 12, 100–112 (2010). https://doi.org/10.1007/s11940-010-0060-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-010-0060-2

Keywords

Search

Navigation